Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
PMID: 27231280
2016
The Journal of antimicrobial chemotherapy
Abstract: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate RAMs studied were K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in the RT.
Expansion of the E138A mutation in newly diagnosed HIV-infected patients in Gran Canaria.
PMID: 27352730
2016
Diagnostic microbiology and infectious disease
Abstract: We studied 25 HIV newly diagnosed patients with the E138A mutation since the year 2010.
Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
Abstract: The ten major integrase mutations (including N155H, Y143C/R, Q148H/R, Y143Y/H, L74L/M, E92Q, E138E/A, Y143C, Q148Q and Y143S) can reduce the sensitivity of RAL and EVG.
Discussion: The ten major integrase mutations(including N155H, Y143C/R, Q148H/R, Y143Y/H, L74L/M, E92Q, PMID: 27645238
2016
Antimicrobial agents and chemotherapy
Figure: Primary INSTI resistance mutations are T66I/A/K, E92Q/G, T97A, Y143C/H/R, S147G, Q148H/K/R, and N155H, and other INSTI resistance mutations are H51Y, L68I/V, V72A/N/T, L74M, Q95K/R, F121C/Y, A128T, E138A/K, G140A/C/S, P145S, PMID: 27697032
2016
Current HIV research
Abstract: The prevalence of DRMs to rilpivirine for E138A/G was 5.7%.
HIV Drug Resistance in Antiretroviral Treatment-Naive Individuals in the Largest Public Hospital in Nicaragua, 2011-2015.
Result: One included MSM with a singleton M41L mutation; the other combined females and males (both MSM and heterosexual) with the E138A mutation.
Result: The presence of individuals with both recent and long-standing infection in the clusters suggests long-term stability of the M41L and E138A mutations.
Result: This increase was mainly NNRTI-associated due to the presence of the polymorphic mutation E138A (86% of cases) and to a lesser extent V108I (14% of cases), which ar
Figure: NNRTI PDR mutation frequency trends; only surveillance drug resistance mutations to NNRTI with frequency over 0.5% and E138A are included.
Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
Discussion: Besides the Q148 mutation combined with one or more of G140A/C/S, L74I and E138A/K/T was identified to reduce viral susceptibility to dolutegravir, two amino acid mutations, G118R and R263K, have been reported to confer low-level resistance to dolutegravir.
Discussion: In patients experiencing virological failure to the first generation of INSTIs, raltegravir and elvitegravir, three genotypic mutation pathways have been defined: Q148H/R/K (+-G140S or E138A/K), N155H (+-E92Q), and Y143C/H/R (+- PMID: 27957489
2016
BioMed research international
Result: The mutations with a low effect on the resistance to NNRTIs (E138A, V108I, and V90I) also had a low prevalence.
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
PMID: 25344807
2015
The Journal of antimicrobial chemotherapy
Abstract: Rilpivirine RAMs were detected in 41 (32%) individuals, with highest frequency for the mutations Y181C/I/V (18%), K101E/P (7%) and E138A/G/K/Q/R/S (6%) and the association L100I+K103N/S (5%).
Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.
PMID: 25582324
2015
AIDS research and human retroviruses
Result: Among all the mutations detected, T74S (54.5%) in PR and E138A (17%), V179I (16%), followed by V118I and V179E (14% each) in RT were the most prevalent, while T69NS, V90I, and V106I were present at only 5% each.
Result: Five specimens had A98G, K101EK, V108IV, K103N, E138A, and G190A occurring alone or in combination with each other, which could cause intermediate and/or high-level resistance to delavirdine (D
HIV mutation literature information.
PMID: 
2016
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT